临床试验/NCT04710056

NCT04710056Available不适用

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Regeneron Pharmaceuticals0 个研究点开始时间: 2021年1月14日最近更新: 2026年3月12日

研究概览

简要总结

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

详细描述

Expanded Access requests are only being considered in response to Individual Patient and Intermediate-Size Population EAP Investigational New Drug (IND) applications. Availability will depend on location.

研究设计

研究类型: Expanded Access

入排标准

性别: All
接受健康志愿者: 否

入选标准

•Key Inclusion: N/A

排除标准

•Exclusion: N/A

研究者

发起方

Regeneron Pharmaceuticals

申办方类型

Industry

责任方

Sponsor

相似试验

No Longer Available

不适用

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic SyndromesMyelodysplastic Syndromes

NCT04484363Takeda

No Longer Available

不适用

This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma

NCT00720603Genzyme, a Sanofi Company

已完成

2 期

Trial of Leptin Replacement Therapy in Patients With LipodystrophyHypoleptinemiaGeneralized LipodystrophyPartial LipodystrophyInsulin Resistance

NCT00896298University of Texas Southwestern Medical Center25

招募中

不适用

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)Diabetic Retinopathy

NCT03403686University of Alabama at Birmingham104

Unknown

不适用

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic CancerPancreatic Cancer

NCT04087889Hope Biosciences LLC